Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019	[1]
Current assets:
Cash and cash equivalents	$ 221,849	$ 57,937
Short-term investments	560,583	130,333
Receivable from collaboration partners	2,579	132
Accrued interest receivable	372	251
Prepaid expenses and other current assets	11,816	4,052
Total current assets	797,199	192,705
Long-term investments	2,700
Property and equipment, net	8,728	9,330
Restricted cash	203	203
Other long-term assets	2,245	872
Total assets	811,075	203,110
Current liabilities
Accounts payable	8,102	4,704
Accrued research and development expenses	28,237	4,572
Other accrued liabilities	7,496	4,950
Deferred revenue, current	115,614	7,000
Other current liabilities	3,422	1,480
Total current liabilities	162,871	22,706
Deferred revenue, noncurrent	91,298	12,022
Deferred rent, noncurrent	4,311	3,734
Other long-term liabilities	8,178	806
Total liabilities	266,658	39,268
Stockholders’ equity:
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of September 30, 2020 and December 31, 2019; no shares issued and outstanding as of September 30, 2020 and December 31, 2019	0	0
Common stock, $0.0001 par value, 400,000,000 shares authorized as of September 30, 2020 and December 31, 2019; 64,924,073 and 45,925,004 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively	6	4
Additional paid-in capital	820,661	369,100
Accumulated deficit	(276,331)	(205,326)
Accumulated other comprehensive income	81	64
Total stockholders’ equity	544,417	163,842	[2]
Total liabilities and stockholders’ equity	$ 811,075	$ 203,110

[1] The Condensed Consolidated Balance Sheet as of December 31, 2019 has been derived from the audited financial statements as of that date.

[2] The balances as of December 31, 2019 and 2018 have been derived from the audited financial statements as of that date.